Brind.

CORT submitted an FDA application for relacorilant, while AI stocks continue to benefit from Trump-era tariffs.

2 reports, 1 independent Updated Jul 25

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CORT submitted an FDA application for relacorilant, while AI stocks continue to benefit from Trump-era tariffs.

Who's involved

What this event is mainly about

FDA Donald Trump BioPharma

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
BioPharma
company in Jílové u Prahy, Czech Republic
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.Mon 02:47
- BioPharma and Milestone Pharmaceuticals are small-cap healthcare companies.Wed 08:33

Coverage

Newest first; wire copies grouped

Jul 25Insider MonkeyCorcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT
Jul 23Insider MonkeyCorcept Advances Cancer Drug as Analysts Back Strong Growth Prospects Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are reiteratin